Lifeline for patients: pfizer extends crizotinib access in ongoing study

NCT ID NCT05160922

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 21 times

Summary

This study offers continued access to the drug crizotinib for people with certain cancers (NSCLC, ALCL, IMT) who are already benefiting from it in a previous Pfizer study that is ending. The main goal is to track long-term safety, not to test if the drug works. About 27 participants will take the drug as long as it helps them and side effects are manageable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • ASST Monza

    Monza, MB, 20900, Italy

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

  • Cancer Hospital Chinese Academy of Medical Science

    Beijing, Beijing Municipality, 100021, China

  • Fujian Province Oncology Hospital

    Fuzhou, Fujian, 350014, China

  • Jilin Cancer Hospital

    Changchun, Jilin, 130028, China

  • Limited Liability Company "EuroCityClinic"

    Saint Petersburg, 197022, Russia

  • National Hospital Organization Nagoya Medical Center

    Nagoya, Aichi-ken, 460-0001, Japan

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

  • Shanghai Chest Hospital

    Shanghai, 200030, China

  • Sun Yat-Sen University Cancer center

    Guangzhou, Guangdong, 510060, China

  • The First Affiliated Hospital of College of Medicine,Zhejiang University

    Hangzhou, Zhejiang, 310003, China

  • The First Affiliated Hospital of Guangzhou Medical University.

    Guangzhou, Guangzhou, 510120, China

  • West China Hospital of Sichuan University

    Wuhou District, Sichuan, 610041, China

Conditions

Explore the condition pages connected to this study.